We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Handheld Immunoanalyzer Performs Laboratory Tests near Patient without Sacrificing Sensitivity and Precision

By LabMedica International staff writers
Posted on 22 Mar 2023

Near Patient Testing (NPT), also known as Point of Care Testing (POCT), is a rapidly growing area within the field of In vitro diagnostics (IVDs). More...

NPT is now recognized for its key role in making services more patient-centered by bringing diagnostic testing closer to the patient. This shift has the potential to significantly transform the way healthcare services are delivered to patients. By enabling timely diagnosis at the bedside, in community settings, or even in general practice, the delivery of care can be made much more efficient, allowing patients to receive the right diagnosis and treatment in a timely and convenient manner. Now, a handheld portable immunoanalyzer with the sensitivity and precision of centralized laboratory equipment is currently being developed in a form factor suitable for low-cost, point-of-care testing anywhere in the world.

Proxim Diagnostics Corp. (Santa Clara, CA, USA) is developing the Profile System, a portable and fully automated immunodiagnostic device that can run several types of multiplexed assays using disposable cartridges. The system performs critical laboratory tests near the patient using whole blood without sacrificing sensitivity and precision to deliver the most critical information to the doctors right when they need it. The Profile System is battery operated, and offers a touch-screen display interface, along with wireless, Ethernet, and USB connectivity.

The handheld device is expected to enhance the ability of clinicians to perform rapid, high-quality testing at the point of care, such as in emergency rooms, intensive care units, nursing homes, community/remote clinics and in-home care, as well as in disaster relief and defense situations. The system is currently available for research use only. Proxim is also developing several immunoassays for sepsis, cardiology, and infectious diseases that can match the sensitivity and precision of tests that are run on larger, centralized laboratory equipment.

Related Links:
Proxim Diagnostics Corp.


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.